{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T02:02:45Z","timestamp":1783735365264,"version":"3.55.0"},"reference-count":75,"publisher":"Oxford University Press (OUP)","issue":"19","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,10,1]]},"DOI":"10.2146\/ajhp140031","type":"journal-article","created":{"date-parts":[[2014,9,15]],"date-time":"2014-09-15T13:59:46Z","timestamp":1410789586000},"page":"1621-1634","source":"Crossref","is-referenced-by-count":25,"title":["Antibiotic dosing in cirrhosis"],"prefix":"10.1093","volume":"71","author":[{"given":"Jenana","family":"Halilovic","sequence":"first","affiliation":[{"name":"Infectious Diseases, Department of Pharmaceutical Services, University of California Davis Health System, Sacramento."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett H.","family":"Heintz","sequence":"additional","affiliation":[{"name":"Internal Medicine and Infectious Diseases, Department of Pharmaceutical Services, Iowa City Veterans Affairs Healthcare System"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","reference":[{"key":"2019041211203617000_b1-0711621","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.dld.2013.07.015","article-title":"Management of infections in cirrhotic patients: report of a consensus conference","volume":"46","author":"Fagiuoli","year":"2014","journal-title":"Dig Liver Dis"},{"key":"2019041211203617000_b2-0711621","first-page":"900","article-title":"The importance of bacterial infections as precipitating factors of chronic hepatic encephalopathy in cirrhosis","volume":"45","author":"Strauss","year":"1998","journal-title":"Hepatogastroenterology"},{"key":"2019041211203617000_b3-0711621","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S1590-8658(01)80134-1","article-title":"Bacterial infection in patients with advanced cirrhosis: a multicentre prospective study","volume":"33","author":"Borzio","year":"2001","journal-title":"Dig Liver Dis"},{"key":"2019041211203617000_b4-0711621","doi-asserted-by":"crossref","first-page":"529","DOI":"10.2165\/00002018-200528060-00005","article-title":"Dose adjustment in patients with liver disease","volume":"28","author":"Delco","year":"2005","journal-title":"Drug Saf"},{"key":"2019041211203617000_b5-0711621","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/apt.12324","article-title":"Review article: prescribing medications in patients with cirrhosis\u2014a practical guide","volume":"37","author":"Lewis","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"2019041211203617000_b6-0711621","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s00228-008-0553-z","article-title":"Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction","volume":"64","author":"Verbeeck","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"2019041211203617000_b7-0711621","doi-asserted-by":"crossref","first-page":"46","DOI":"10.2165\/00003088-199324010-00004","article-title":"Clinical pharmacokinetics of newer antibacterial agents in liver disease","volume":"24","author":"Westphal","year":"1993","journal-title":"Clin Pharmacokinet"},{"key":"2019041211203617000_b8-0711621","doi-asserted-by":"crossref","first-page":"370","DOI":"10.2165\/00003088-199529050-00005","article-title":"Clinical pharmacokinetic and pharmacodynamic considerations in patients with liver disease. An update","volume":"29","author":"Morgan","year":"1995","journal-title":"Clin Pharmacokinet"},{"key":"2019041211203617000_b9-0711621","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1592\/phco.30.8.776","article-title":"Evaluation of renal drug dosing: prescribing information and clinical pharmacist approaches","volume":"30","author":"Dowling","year":"2010","journal-title":"Pharmacotherapy"},{"key":"2019041211203617000_b10-0711621","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal varices","volume":"60","author":"Pugh","year":"1973","journal-title":"Br J Surg"},{"key":"2019041211203617000_b11-0711621","doi-asserted-by":"crossref","first-page":"297","DOI":"10.2165\/00003088-197601040-00004","article-title":"Pharmacokinetics of the penicillins in man","volume":"1","author":"Barza","year":"1976","journal-title":"Clin Pharmacokinet"},{"key":"2019041211203617000_b12-0711621","first-page":"12","article-title":"Penicillin handling in normal and azotemic patients","volume":"74","author":"Plaut","year":"1969","journal-title":"J Lab Clin Med"},{"key":"2019041211203617000_b13-0711621","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/S0016-5085(19)31519-7","article-title":"Disposition of nafcillin in patients with cirrhosis and extrahepatic biliary obstruction","volume":"73","author":"Marshall","year":"1977","journal-title":"Gastroenterology"},{"key":"2019041211203617000_b14-0711621","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/j.1875-9114.1982.tb03185.x","article-title":"Mechanism of action, antimicrobial activity, pharmacology, adverse effects, and clinical efficacy of cefotaxime","volume":"2","author":"LeFrock","year":"1982","journal-title":"Pharmacotherapy"},{"key":"2019041211203617000_b15-0711621","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1128\/AAC.35.7.1376","article-title":"Pharmacokinetics of cefotaxime and desacetyl-cefotaxime in patients with liver disease","volume":"35","author":"Ko","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"2019041211203617000_b16-0711621","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/BF00637745","article-title":"The pharmacokinetics of ceftriaxone and cefotaxime in cirrhotic patients with ascites","volume":"36","author":"Hary","year":"1989","journal-title":"Eur J Clin Pharmacol"},{"issue":"suppl B","key":"2019041211203617000_b17-0711621","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/jac\/14.suppl_B.143","article-title":"Cefotaxime and desacetyl-cefotaxime blood levels in hepatic dysfunction","volume":"14","author":"Graninger","year":"1984","journal-title":"J Antimicrob Chemother"},{"key":"2019041211203617000_b18-0711621","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2165\/00003088-198510020-00001","article-title":"Clinical pharmacokinetics of the third generation cephalosporins","volume":"10","author":"Balant","year":"1985","journal-title":"Clin Pharmacokinet"},{"key":"2019041211203617000_b19-0711621","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1038\/clpt.1984.210","article-title":"Single-dose ceftriaxone kinetics in liver insufficiency","volume":"36","author":"Stoeckel","year":"1984","journal-title":"Clin Pharmacol Ther"},{"key":"2019041211203617000_b20-0711621","volume-title":"Cefepime injection package insert","year":"2013"},{"key":"2019041211203617000_b21-0711621","volume-title":"Teflaro (ceftaroline fosamil) injection package insert","year":"2013"},{"key":"2019041211203617000_b22-0711621","doi-asserted-by":"crossref","first-page":"233S","DOI":"10.1592\/phco.21.16.233S.33992","article-title":"Pharmacokinetics and pharmacodynamics of fluoroquinolones","volume":"21","author":"Rodvold","year":"2001","journal-title":"Pharmacotherapy"},{"issue":"suppl B","key":"2019041211203617000_b23-0711621","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1093\/jac\/26.suppl_B.41","article-title":"Quinolone pharmacokinetics and metabolism","volume":"26","author":"Lode","year":"1990","journal-title":"J Antimicrob Chemother"},{"key":"2019041211203617000_b24-0711621","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/clpt.1989.81","article-title":"The effect of cirrhosis on the steady-state pharmacokinetics of oral ciprofloxacin","volume":"45","author":"Frost","year":"1989","journal-title":"Clin Pharmacol Ther"},{"key":"2019041211203617000_b25-0711621","first-page":"62","article-title":"Pharmacokinetics of ciprofloxacin in patients with liver cirrhosis","volume":"21","author":"Dixit","year":"2002","journal-title":"Ind J Gastroenterol"},{"key":"2019041211203617000_b26-0711621","volume-title":"Avelox (moxifloxacin) package insert","year":"1999"},{"key":"2019041211203617000_b27-0711621","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/jac\/dkn212","article-title":"Single- and multiple-dose pharmacokinetics of intravenous moxifloxacin in patients with severe hepatic impairment","volume":"62","author":"Barth","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"suppl 1","key":"2019041211203617000_b28-0711621","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1007\/BF01650510","article-title":"Efficacy and safety of ciprofloxacin in the treatment of UTIs and RTIs in patients affected by liver diseases","volume":"16","author":"Esposito","year":"1988","journal-title":"Infection"},{"key":"2019041211203617000_b29-0711621","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/hep.1840120416","article-title":"Norfloxacin prevents spontaneous bacterial peritonitis recurrence in cirrhosis: results of a double-blind, placebo-controlled trial","volume":"12","author":"Gines","year":"1990","journal-title":"Hepatology"},{"key":"2019041211203617000_b30-0711621","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/j.1365-2125.1987.tb03111.x","article-title":"Pharmacokinetics of erythromycin in patients with severe cirrhosis. Respective influence of decreased serum binding and impaired liver metabolic capacity","volume":"23","author":"Barre","year":"1987","journal-title":"Br J Clin Pharmacol"},{"key":"2019041211203617000_b31-0711621","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1128\/AAC.21.1.135","article-title":"Pharmacokinetics of single-dose erythromycin in normal and alcoholic liver disease subjects","volume":"21","author":"Kroboth","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"2019041211203617000_b32-0711621","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/j.1552-4604.1982.tb02682.x","article-title":"Pharmacokinetics of erythromycin in normal and alcoholic liver disease subjects","volume":"22","author":"Hall","year":"1982","journal-title":"J Clin Pharmacol"},{"key":"2019041211203617000_b33-0711621","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1002\/j.1552-4604.1993.tb04692.x","article-title":"Effect of moderate or severe hepatic impairment on clarithromycin pharmacokinetics","volume":"33","author":"Chu","year":"1993","journal-title":"J Clin Pharmacol"},{"issue":"suppl E","key":"2019041211203617000_b34-0711621","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/jac\/31.suppl_E.57","article-title":"Pharmacokinetics of azithromycin in patients with impaired hepatic function","volume":"31","author":"Mazzei","year":"1993","journal-title":"J Antimicrob Chemother"},{"key":"2019041211203617000_b35-0711621","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.2165\/00003088-200342130-00004","article-title":"Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial","volume":"42","author":"Stalker","year":"2003","journal-title":"Clin Pharmacokinet"},{"issue":"suppl A","key":"2019041211203617000_b36-0711621","first-page":"55","article-title":"Pharmacokinetics of linezolid in patients with liver disease","volume":"44","author":"Hendershot","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"2019041211203617000_b37-0711621","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s10156-008-0587-2","article-title":"Pharmacokinetics of repeated dosing of linezolid in a hemodialysis patient with chronic renal failure","volume":"14","author":"Tsuji","year":"2008","journal-title":"J Infect Chemother"},{"key":"2019041211203617000_b38-0711621","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/j.1440-1843.2006.00941.x","article-title":"Antituberculosis drugs and hepatotoxicity","volume":"11","author":"Yew","year":"2006","journal-title":"Respirology"},{"key":"2019041211203617000_b39-0711621","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1440-1746.2007.05207.x","article-title":"Antituberculosis drug-induced hepatotoxicity: concise up-to-date review","volume":"23","author":"Tostmann","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"2019041211203617000_b40-0711621","doi-asserted-by":"crossref","first-page":"327","DOI":"10.2165\/00003088-200140050-00002","article-title":"Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials","volume":"40","author":"Burman","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"2019041211203617000_b41-0711621","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1136\/gut.13.1.47","article-title":"Kinetics of rifampicin and isoniazid administered alone and in combination to normal subjects and patients with liver disease","volume":"13","author":"Acocella","year":"1972","journal-title":"Gut"},{"key":"2019041211203617000_b42-0711621","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000221455","article-title":"Studies on blood serum levels of rifampicin in patients with normal and impaired liver function","volume":"19","author":"Curci","year":"1973","journal-title":"Chemotherapy"},{"key":"2019041211203617000_b43-0711621","volume-title":"Pharmacokinetics of rifabutin in hepatic insufficiency","author":"Benedetti"},{"key":"2019041211203617000_b44-0711621","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1093\/jac\/dkl224","article-title":"Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines","volume":"58","author":"Agwuh","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2019041211203617000_b45-0711621","doi-asserted-by":"crossref","first-page":"355","DOI":"10.2165\/00003088-198815060-00001","article-title":"Clinical pharmacokinetics of doxycycline and minocycline","volume":"15","author":"Saivin","year":"1988","journal-title":"Clin Pharmacokinet"},{"key":"2019041211203617000_b46-0711621","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1097\/MEG.0b013e3282f493c5","article-title":"Minocycline hepatitis","volume":"20","author":"Ford","year":"2008","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2019041211203617000_b47-0711621","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1177\/0091270010363477","article-title":"Pharmacokinetics and safety of a single intravenous dose of the antibiotic tigecycline in patients with cirrhosis","volume":"51","author":"Korth-Bradley","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"2019041211203617000_b48-0711621","volume-title":"Cleocin phosphate (clindamycin) injection package insert","year":"2013"},{"key":"2019041211203617000_b49-0711621","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1128\/AAC.9.3.498","article-title":"Use of clindamycin in patients with liver disease","volume":"9","author":"Hinthorn","year":"1976","journal-title":"Antimicrob Agents Chemother"},{"key":"2019041211203617000_b50-0711621","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF01070725","article-title":"The effect of cirrhosis on the disposition and elimination of clindamycin","volume":"20","author":"Avant","year":"1975","journal-title":"Am J Dig Dis"},{"key":"2019041211203617000_b51-0711621","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1128\/AAC.7.2.153","article-title":"Parenteral clindamycin phosphate: pharmacology with normal and abnormal liver function and effect on nasal staphylococci","volume":"7","author":"Williams","year":"1975","journal-title":"Antimicrob Agents Chemother"},{"key":"2019041211203617000_b52-0711621","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1201\/b13787-90","article-title":"Lincomycin and clindamycin","volume-title":"Kucers\u2019 the use of antibiotics","author":"Kluytmans","year":"2010","edition":"6th ed"},{"key":"2019041211203617000_b53-0711621","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2165\/00003088-199936050-00004","article-title":"Pharmacokinetics and pharmacodynamics of the nitroimidazole antimicrobials","volume":"36","author":"Lamp","year":"1999","journal-title":"Clin Pharmacokinet"},{"key":"2019041211203617000_b54-0711621","doi-asserted-by":"crossref","first-page":"117","DOI":"10.3109\/00365528708991867","article-title":"Metronidazole pharmacokinetics in patients with hepatic encephalopathy","volume":"22","author":"Loft","year":"1987","journal-title":"Scand J Gastroenterol"},{"key":"2019041211203617000_b55-0711621","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1128\/AAC.31.11.1662","article-title":"Pharmacokinetics of metronidazole in patients with alcoholic liver disease","volume":"31","author":"Lau","year":"1987","journal-title":"Antimicrob Agents Chemother"},{"key":"2019041211203617000_b56-0711621","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2125.1995.tb05792.x","article-title":"Plasma hydroxy-metronidazole\/metronidazole ratio in patients with liver disease and in healthy volunteers","volume":"40","author":"Muscara","year":"1995","journal-title":"Br J Clin Pharmacol"},{"key":"2019041211203617000_b57-0711621","first-page":"342","article-title":"Drug therapy reviews: nitrofurantoin","volume":"36","author":"Gleckman","year":"1979","journal-title":"Am J Hosp Pharm"},{"key":"2019041211203617000_b58-0711621","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1476-5381.1973.tb06913.x","article-title":"Further studies on nitrofurantoin excretion in dog hepatic bile","volume":"48","author":"Conklin","year":"1973","journal-title":"Br J Clin Pharmacol"},{"key":"2019041211203617000_b59-0711621","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1021\/jm50012a007","article-title":"Metabolic degradation of the nitrofurans","volume":"2","author":"Paul","year":"1960","journal-title":"J Med Pharm Chem"},{"key":"2019041211203617000_b60-0711621","first-page":"76","article-title":"Pharmacokinetics of pyrazinamide and its metabolites in patients with hepatic cirrhotic insufficiency","volume":"40","author":"Lacroix","year":"1990","journal-title":"Arzneimittelforschung"},{"key":"2019041211203617000_b61-0711621","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1592\/phco.20.19.1469.34858","article-title":"Quinupristin-dalfopristin: an overview","volume":"20","author":"Delgado","year":"2000","journal-title":"Pharmacotherapy"},{"key":"2019041211203617000_b62-0711621","volume-title":"Open, comparative, study of the pharmacokinetics and safety of a single dose of quinupristin\/dalfopristin (Q\/D, RP 59500, Synercid) in subjects with hepatic cirrhosis and healthy volunteers","author":"Chevalier","year":"1997"},{"key":"2019041211203617000_b63-0711621","volume-title":"Bactrim (sulfamethoxazole and trimethoprim) package insert","year":"2005"},{"key":"2019041211203617000_b64-0711621","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/j.1440-1746.2007.04926.x","article-title":"Norfloxacin and trimethoprim-sulfamethoxazole therapy have similar efficacy in prevention of spontaneous bacterial peritonitis","volume":"23","author":"Lontos","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"2019041211203617000_b65-0711621","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/clpt.2008.262","article-title":"Monitoring for hepatotoxicity: what is the predictive value of liver \u201cfunction\u201d tests","volume":"85","author":"Senior","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"2019041211203617000_b66-0711621","first-page":"519526","article-title":"Prescribing medications in patients with decompensated liver cirrhosis","volume":"2011","author":"Amarapurkar","year":"2011","journal-title":"Int J Hepatol"},{"key":"2019041211203617000_b67-0711621","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2165\/00002018-200730040-00001","article-title":"Drug-induced liver injury","volume":"30","author":"Abboud","year":"2007","journal-title":"Drug Saf"},{"key":"2019041211203617000_b68-0711621","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1136\/gut.2008.163675","article-title":"Diagnosis, management and prevention of drug-induced liver injury","volume":"58","author":"Verma","year":"2009","journal-title":"Gut"},{"key":"2019041211203617000_b69-0711621","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2165\/00003088-199937050-00004","article-title":"Effects of liver disease on pharmacokinetics. An update","volume":"37","author":"Rodighiero","year":"1999","journal-title":"Clin Pharmacokinet"},{"issue":"suppl 2","key":"2019041211203617000_b70-0711621","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1086\/381446","article-title":"Drug-induced liver injury","volume":"38","author":"Kaplowitz","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2019041211203617000_b71-0711621","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1053\/j.gastro.2010.04.001","article-title":"Risk factors for idiosyncratic drug-induced liver injury","volume":"138","author":"Chalasani","year":"2010","journal-title":"Gastroenterology"},{"key":"2019041211203617000_b72-0711621","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1089-3261(03)00021-7","article-title":"Hepatotoxicity of antibiotics and antifungals","volume":"7","author":"Thiim","year":"2003","journal-title":"Clin Liver Dis"},{"key":"2019041211203617000_b73-0711621","volume-title":"Lexicomp Online [online database]"},{"key":"2019041211203617000_b74-0711621","volume-title":"Micromedex 2.0 [online database]"},{"key":"2019041211203617000_b75-0711621","unstructured":"National Institutes of Health. Livertox: clinical and research information on drug-induced liver injury [online database]. http:\/\/livertox.nih.gov\/ (accessed 2014 Apr 1)."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/71\/19\/1621\/28373481\/ajhp1621.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,14]],"date-time":"2019-08-14T20:31:16Z","timestamp":1565814676000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/71\/19\/1621\/5111052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10,1]]},"references-count":75,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2014,10,1]]}},"URL":"https:\/\/doi.org\/10.2146\/ajhp140031","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2014,10,1]]},"published":{"date-parts":[[2014,10,1]]}}}